As per reports, Johnson & Johnson (JNJ) had formally informed Emergent BioSolutions Inc. of its decision to terminate the agreement with the contract manufacturer to make the COVID-19 vaccine for the drugmaker. Earlier, Emergent informed that J&J breached an agreement by failing to buy the minimum quantity of COVID-19 vaccines made by the company.
The contract manufacturer added that J&J had failed to provide required forecasts for the number of vaccines it needed and had wound down the agreement instead of fulfilling minimum requirements.
The use of J&J’s COVID-19 vaccine has been stopped in the United States after the Food and Drug Administration in May significantly restricted its use due to blot clot concerns.
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.